Strategic Milestones

Until mid-2018
LSB MedTech, together with Maastricht University, served as co-owner and investor in Vitak Group Ltd., formerly recognized as the world’s largest MGP-focused CRO laboratory. Within this organization, a dedicated medical technology division was established to support innovations related to vascular elasticity monitoring and anticoagulant research. The pharmaceutical division concentrated on vitamin K antagonists and studies related to vascular calcification.

Mid-2018
In collaboration with several academic institutions, LSB MedTech established its own CRO laboratory. This facility provided specialized CRO services to pharmaceutical companies and the food industry, supporting both clinical and applied research activities across these sectors.

Mid-2021
LSB MedTech expanded its operations by introducing innovation consultancy services for nursing homes and hospitals. This initiative focused on supporting the development and implementation of innovative healthcare solutions aimed at improving care processes and enhancing patient support systems.

Mid-2023
The CRO laboratory activities were acquired by a Japanese CRO organization. Following this divestment, LSB MedTech redirected its strategic focus entirely toward medical innovation technology, patient-care technology, innovation consultancy, and IP valorization. These activities are now managed from the company’s headquarters in the United Arab Emirates and China, with additional operations maintained in the Netherlands.